A mosquito on a person’s skin. File Picture: Malaria afflicts more than 200 million people in the developing world each year. Picture: African News Agency (ANA) Archives
Durban - As Gauteng issued a malaria warning, the National Institute for Communicable Diseases (NICD) in a statement on Monday said it remains one of the most devastating parasitic diseases affecting humans.
This comes after IOL reported that the Gauteng Health Department had issued a malaria warning after more than 1 000 cases and 11 deaths were recorded between January and September in the province.
In the report, provincial Health MEC Nomantu Nkomo-Ralehoko called on community members, especially people who recently travelled to and from malaria endemic areas, to seek medical treatment if they experience malaria-related symptoms, which include fever, chills, headache and other flu-like symptoms.
“It remains worrying that from January to September 2022 Gauteng as a province, recorded 1 103 cases with 11 deaths. Most of malaria cases recorded in the province are from Mozambique, followed by Malawi, Zimbabwe and Ethiopia,” said Nkomo-Ralehoko.
The NICD said in 2020, there were around 241 million cases and 672 000 malaria-related deaths.
The NICD said one of the reasons why malaria is so persistent is that the malaria parasite has a very complex life cycle. It involves many different developmental stages and multiple hosts (mosquitoes and humans).
“In Africa, what adds to the challenge of controlling malaria is that the continent is home to some of the most efficient malaria vectors. These include Anopheles gambiae and An. funestus. Also, the malaria parasite species Plasmodium falciparum, the dominant species in Africa, is the most lethal. It’s responsible for most malaria cases and deaths – 80% of which occur in children younger than five.”
According to the NICD, the elimination of malaria is still a challenge and only two African countries, Algeria and Morocco, have been certified as malaria-free by the World Health Organization (WHO).
The NICD lists some of the reasons why malaria elimination targets in African countries remain out of reach:
Poverty
Mobility
Resistance
Climate change
The NICD said in spite of these challenges, there are two new malaria vaccines.
The first, Mosquirix, has been pre-qualified for use by the WHO. The second, R21/Matrix M, has shown promising results in phase 2 clinical trials.
“There are new long-lasting insecticide treated nets and insecticide formulations for vector control. There are also novel strategies for parasite suppression. Adding these tools to the elimination toolbox will assist Africa to get closer to malaria elimination.”
Related Topics: